PEWAUKEE, Wis., May 15, 2025 /PRNewswire/ -- BiaCure Therapies, an emerging innovator in non-invasive medical technology, today announced it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health (NIH) in the amount of $2.6M over three years to support the development of its proprietary high-frequency energy (HFE) therapy system for the treatment of onychomycosis, a chronic and stubborn fungal infection of the nail. The funding will be u

Merck KGaA now expects sales from its life science arm—which provides R&D and CDMO services, plus key materials for partners—to land between 8.8 billion euros and 9.4 billion euros in 2025. As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the broader biopharma industry.For the full year, Merck now expects sales from its life science arm—which provides R&D and CDMO services plus key materials for partners—to lan

100% of patients with Glean were able to void with the sensor indwelling. IRVINE, Calif., May 15, 2025 /PRNewswire/ -- Bright Uro, a medical device company with a mission to transform care for lower urinary tract dysfunction (LUTD) through innovations in urodynamics, today announced that its recent feasibility study was published in the Journal of Endourology. Results showed that the Glean™ Urodynamics System is a safe, and well-tolerated device that enables ambulatory urodynamics without cathet

Abstracts mit Schwerpunkt auf hypothermer oxygenierter Perfusion (HOPE) bei Lebertransplantationen, einschließlich pädiatrischer Patienten CHICAGO, 15. Mai 2025 /PRNewswire/ -- Bridge to Life™ Ltd., ein führender Anbieter von Lösungen zur Organderhaltung und Perfusionstechnologie, gab heute die Präsentation von neun angenommenen Abstracts, darunter zwei Late-Breaker, auf dem 2025 International Congress of the International Liver Transplantation Society (ILTS) bekannt. Die Konferenz findet vom 28

The Blavatnik Family Foundation's Longtime Support of Pioneering Researcher Evgeny Nudler's Work Holds Promise for Advances in Cancer Therapy, Antibiotic Resistance, and Anti-Aging NEW YORK, May 15, 2025 /PRNewswire/ -- NYU Langone Health today announced a $15 million gift from the Blavatnik Family Foundation to support research led by Evgeny Nudler, PhD, the Julie Wilson Anderson Professor in the Department of Biochemistry and Molecular Pharmacology and Investigator with the Howard Hughes Medic

Co-development of precision RNA therapeutics for inherited hearing loss treatment SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and commercialize novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform. The collabor

Duchemin brings global MedTech leadership experience to accelerate Fotona's next phase of growth DALLAS , May 15, 2025 /PRNewswire/ -- Fotona Ⓡ, a global leader in high-performing laser systems and energy-based devices for aesthetic, dental and gynecological applications, today announces the appointment of Jeff Duchemin as Group President and CEO. Continue Reading Jeff Duchemin, CEO Fotona Duchemin brings decades of leadership experience in the global medical technology sector, having held seni

Merck's Welireg has been approved in its third indication, as a treatment for rare pheochromocytoma or paraganglioma tumors in the endocrine system. Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown jewel of the deal.On Wednesday, the FDA approved a third indication for Welireg (belzutifan), signing off on the hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor to treat patients with rare pheochromocytoma or paragan

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert i

In addition to funding its clinical work, Pathos AI stated that this morning’s series D would be used to further invest in its artificial intelligence platform.\n Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics.The company can now lay claim to a post-money valuation of around $1.6 billion, according to a May 15 release. At the top of Pathos’ sp